If MSB is to be removed from S&P ASX 200...., page-181

Hottuna

You don't seem to understand that the CEO gave us background at the AGM. It's the sort of background that an educated biotech investor would already know: that the valuations and costs analysis involved is highly complex and involves many iterations. Therefore giving one party exclusive access over a period gives them an advantage.

This is NOT market sensitive information and it's a slur to suggest that the CEO might be having us on.

You seem to think that a bunch of revved up commentators who wanted to redirect discussion are justified? There was very little time to cover a range of issues that they decided they must have answered when they KNOW that it's commercial inconfidence.

You think it's OK to slur the CEO as some kind of spruiker?

I've answered some of this with my response to Kalala. I've got things to do. It seems some of you are in here fulltime. That sustained effort suggests a lot of skin in the game. The funniest thing is the suggestion that I'm somehow desperate. Remaining civil in here with this kind of sustained barrage is a challenge.